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Background: The aim of this study was to assess the reconstructive potential of
a submerged healing approach for the treatment of infraosseous peri-implantitis
defects.
Methods: Patients with a diagnosis of peri-implantitis were recruited. Implant
suprastructures were removed before the surgical treatment, which included
implant surface and defect detoxification using implantoplasty, air-power driven
devices, and locally delivered antibiotics. The augmentation procedure included
a composite bone graft and a non-resorbable membrane followed by primary
wound coverage and a submerged healing of 8 months, at which point mem-
branes were removed, and peri-implant defect measurements were obtained as
the primary outcome. Secondary endpoints included assessment of cone-beam
computed tomography (CBCT) and probing depth (PD) reductions.
Results: Thirty implants in 22 patients were treated. A significant clinical bone
gain of 3.22 ± 0.41 mm was observed at 8 months. Radiographic analysis also
showed an average gain of 3.47± 0.41mm. Threemonths after installment of new
crowns, final PD measures showed a significant reduction compared to initial
examinations and a significant reduction in bleeding on probing compared to
examinations at the pre-surgical visit.
Conclusions: Reconstruction of infraosseous peri-implantitis defects is feasi-
ble with thorough detoxification of implant sites, and a submerged regenerative
healing approach.
KEYWORDS
bone regeneration, dental implants, implant failure, peri-implantitis, periodontal diseases, sur-
gical treatment
1 INTRODUCTION
Peri-implantitis is an inflammatory response that leads to
the irreversible loss of implant supporting bone. This con-
dition and is clinically characterized by an implant site that
exhibits signs of inflammation in addition to radiographic
bone loss beyond initial biological bone remodeling.1 Stud-
ies have estimated that peri-implantitis affects approxi-
mately one in every four individuals (22%) with dental
implants,2,3 and is the leading cause of implant failure .4,5
With the emergence of this disease, a variety of thera-
peutic options have been set forward for its management.
J Periodontol. 2021;1–13. © 2021 American Academy of Periodontology 1wileyonlinelibrary.com/journal/jper
2 WEN et al.
Non-surgical therapies alone have generally shown to
be inadequate for treating moderate and severe forms
of peri-implantitis .6–9 Surgical therapies such as open
flap debridement and resective procedures can provide
a greater access to the peri-implant defect for enhanced
debridement and detoxification, as well as for obtaining
probing depth (PD) reduction.7,10 Nonetheless, these have
also been documented with varying levels of success
,10–12 and with failure rates of as high as ≈60% .13 More-
over, in spite of achieving disease resolution, because
peri-implantitis is an irreversible phenomenon, the
implant site after treatment remains devoid of its original
supporting bony structures.
More recently, surgical therapies in combination with
regenerative protocols have been employed, with a range
of biomaterials, adopting many of the principles of guided
bone regeneration (GBR) (i.e., use of bone grafting materi-
als and barrier membranes).14,15 The aim, aside from res-
olution of disease, has been to reconstruct the lost peri-
implant supporting bone .14,16,17 To achieve this aim, two
main approaches have been used throughout the litera-
ture; the submerged approachwherein the implant supras-
tructures (i.e., crowns) are removed and a primary clo-
sure and coverage of the grafted area is obtained, allowing
for undisturbed wound healing, and the non-submerged
approach wherein removal of the suprastructure is not
performed and hence the implant cannot be completely
submerged.
Currently, most of the literature on reconstructive
treatment for peri-implantitis involves a non-submerged
healing approach .18–21 Indeed, the removal of an implant
crown adds extra steps, and accompanies additional
time and costs for both the patient and the clinician.
Nevertheless, it can be speculated that removal of the
implant suprastructures can provide an increased access
to the implant surface for enhanced detoxification, and
that a submerged healing would ultimately create a
more favorable environment for bone formation to occur.
Additionally, the prosthesis itself at times may be a
contributor to the progression and/or initiation of the
disease .22 Thus, even with successful bone regeneration
of a peri-implant defect, adjustment or re-fabrication
of a prosthetic component may be necessary for main-
taining the stability of the treatment outcomes. Thus,
the primary aim of this study was to evaluate the recon-
structive potential, in terms of direct clinical bone gain
measurements for a submerged regenerative approach
when treating infraosseous peri-implantitis defects, as
well as secondarily to evaluate changes in radiographic
bone levels and peri-implant PDs after installment of new
crowns.
2 MATERIALS ANDMETHODS
2.1 Study registration, design, and
participants
The current studywas designed to evaluate the reconstruc-
tive potential of a submerged healing approach for the sur-
gical treatment of peri-implantitis. From June of 2017 to
2019, patients with a diagnosis of peri-implantitis1 in at
least one posterior dental implant who had been on main-
tenance care and at least a biannual professional cleaning
at a university/private practice were assessed for possible
recruitment. The study was conducted at a private office in
Taipei, Taiwan. The diagnosis of peri-implantitis was based
on the definition from the 2017WorldWorkshop1 as a den-
tal implant with bleeding and/or suppuration upon prob-
ing, and increased PD measurements compared to previ-
ous examinations, in combination with radiographic bone
loss beyond initial biological bone remodeling.When lack-
ing previous data, the diagnosis was based on the pres-
ence of bleeding and/or suppuration on probing, with peri-
implant PD measurements of 6 mm or more, with at least
3 mm of radiographic bone loss.
The study protocol was in full accordance with the Dec-
laration of Helsinki of 1965, as revisited in Tokyo in 2013
and approved by the by the Institutional Review Board
and the local ethical committee (Stomatological Hospital
of Xiamen Medical College, #18950051616). The current
article is prepared following the items presented in the
STROBE statement (www.strobe-statement.org, checklist
provided as a supplementary file).
2.2 Eligibility criteria
The following criteria were applied for patients with a
diagnosis of peri-implantitis to be treated as part of this
study: (1) a minimum age of 18 years old, (2) systematically
healthy orwith only amild tomoderate butwell-controlled
systemic disease, (3) bone-level titanium implants with a
vertical defect (of at least 3 mm) and surrounding bony
walls (i.e., a crater-like defects).
The exclusion criteria comprised: (1) patients with
an uncontrolled/untreated systemic or periodontal dis-
ease, (2) subjects on medications known to modify bone
metabolism or those that could interfere with normal
wound healing, (3) patients on recent antibiotic therapy
(within the past 2 months), (4) pregnant, or patients plan-
ning to get pregnant, (5) smoking >10 cigarettes a day,
(6) unable to maintain an adequate oral hygiene (O’Leary
plaque index >50%) ,23 (7) mobile dental implants, (8)
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F IGURE 1 Research timeline demonstrating each study visit from recruitment until the final appointment
implants with defects located outside the bony hous-
ing, and other contraindications for undergoing a dental
surgery.
After successful fulfillment of the inclusion criteria,
details of the study protocol were explained to inter-
ested participants, followed by obtaining an informed
consent. All recruited subjects also underwent localized
non-surgical mechanical debridement (scaling and root
planing) on the infected implants, as well as reinforce-
ment of oral hygiene measures at least 1 month before the
surgical visit (Figure 1).
2.3 Clinical evaluation at the
pre-surgical appointment (time point 0),
and at the final recall (time point 3)
The following clinical parameters were obtained by
a single pre-calibrated study member (S-C.W) at the
pre-surgical appointment immediately before removal
of implant suprastructures, and at the final recall (3
months after installment of new crowns): (1) Peri-implant
PD measurements assessed at six sites (disto-buccal,
buccal, mesio-buccal, mesio-lingual, lingual/palatal,
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disto-lingual) from the mucosal margin to the depth of
the probable peri-implant pocket with a standard peri-
odontal probe* and recorded in millimeter, (2) presence of
bleeding on gentle probing (BOP) assessed dichotomously
as either yes/no within 30 seconds of gentle probing; (3)
suppuration (SUP) on probing assessed dichotomously
(yes/no) after probing, and (4) plaque index (PI) (scores of
0 to 3) .23
2.4 Study protocol
2.4.1 Pre-surgical appointment (time point
0)
The prosthetic superstructures (implant crowns) were
removed 4 to 6 weeks before the surgical treatment for
all implants to undergo regenerative therapy, followed
by placement of cover screws, and a localized superfi-
cial mechanical debridement. Patients were informed that
newly fabricated crowns would be provided after the treat-
ment as part of the study. During this visit, patients were
also re-instructed and emphasized on maintaining proper
at-home oral hygiene measures with a soft-bristled tooth-
brush for minimizing trauma to marginal soft tissues,
which was also reinforced at each subsequent follow-up
interval.
2.4.2 Surgical procedure (time point 1)
All patients received an established treatment protocol by
a single experienced surgeon (S-C.W) under local anes-
thesia as described in a previous report.24 Briefly, an
intrasulcular incision was performed around the implants
for elevation of a full-thickness mucoperiosteal flap on
the buccal and lingual/palatal aspects. Vertical releas-
ing incisions were performed as needed, at a distance
of at least one tooth/implant away from the surgical
site. Next, the peri-implant defects were mechanically
debrided and thoroughly degranulated with periodontal
curettes†.
In case that an implant or a defect did not meet the
inclusion criteria (e.g., non-contained defect, or not fea-
sible for regeneration), the implant/patient was to be
excluded from the study and treated with an apically-
positioned flap approach or an open flap-debridement
procedure.
* PCP-UNC 15; Hu-Friedy, Chicago, IL.
†Gracey curettes; Hu-Friedy, Chicago, IL.
2.4.3 Defect measurements
Vertical measurements of the peri-implant osseous defects
were obtainedusing a periodontal probe‖ at four sites (buc-
cal, lingual/palatal, mesial, distal) from the most coronal
aspect of the implant platform until the depth of the defect
(highest point of bone-to-implant contact) at each site.
2.4.4 Implant detoxification
Implantoplasty was performed on the exposed threads
with rotary instruments‡ under copious irrigation, fol-
lowed by use of an air-abrasive device with glycine pow-
ders §, and the application of a locally delivered antimicro-
bial agent for 5 minutes (Tetracycline, 250 mg and 2.5cc).
2.4.5 Augmentation procedure
Multiple perforations were then made on the cortical
bone with a ¼ round bur. A titanium reinforced non-
resorbable dense Polytetrafluoroethylene (dPTFE) mem-
bran was trimmed to an appropriate size and shape to
completely cover the implant sites and adapted and stabi-
lized linguallywith fixation screws**. Around 10 to 20 holes
were also created on top of the dPTFE membrane with
an explorer to encourage blood supply on top of the ridge
area. Next, a composite bone graft with a combination of
≈60% freeze-dried bone cortical allograft††, 20% mineral-
ized bovine bone‡‡, and 20% autogenous bone (collected
using a bone scraper from the adjacent ramus or maxil-
lary tuberosity)was used to completely fill the peri-implant
defects. Finally, themembranewas stabilized on the buccal
side with at least two fixation screws to ensure a complete
and stable coverage of the grafted area. Care was taken to
ensure that the membrane was resting on bone and not in
contact with adjacent teeth.
2.4.6 Primary wound closure
Periosteal-releasing incisions were performed to allow
passive flap advancement and tension-free displacement.
Monofilament non-resorbable sutures§§ were used for flap
adaptation with horizontal mattress and simple inter-
rupted and/or modified horizontal mattress sutures for
‡Meisinger, Hager & Meisinger, Neuss, Germany
§ AirFlow, EMS, Nyon, Switzerland
** Master Pins, Osteogenics Biomedical, USA
††Maxgraf, Botiss, Zossen, Germany
‡‡Cerabone, Botiss, Zossen, Germany
§§ 4-0, Cytoplast—PTFE suture, Osteogenics Biomedical, USA
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completely covering the augmented site, with the implants
fully submerged.
2.4.7 Post-operative instructions and
interim recall appointments
Detailed post-operative instructions were provided to all
patients, as well as prescriptions for oral systemic antibi-
otics (500 mg of amoxicillin three times a day for 10
days, or 250 mg of Zithromax 6 tablets total /sig. Two
tablets the 1st day once daily until gone), and anal-
gesic medication (600 mg of ibuprofen, taken as needed).
Patients were also recommended to rinse twice daily with
a chlorhexidine-containing mouth rinse (0.12% Chlorhex-
idine mouth rinse) for the first 2 weeks.
Patients were initially recalled at 2 weeks for suture
removal, and then at 6 weeks, 4 months, and 6 months
before the 8-month re-entry for professional oral hygiene
instructions, assessment of soft tissue healing and pos-
sible complications. Subsequently, all participants were
enrolled in a 3-month maintenance program, of which the
initial 3-month recall after installation of the new crowns
served as the final study time point (time point 3) for per-
forming the clinical measurements and re-assessing all
treated sites.
2.4.8 Re-entry procedure and replacement
of suprastructures (time point 2)
After 8months of uninterrupted healing, patients returned
for the re-entry procedure and removal of the non-
resorbable membranes and titanium screws. After mem-
brane removal, the augmented sites were evaluated, and
the same defect measurements taken during the surgi-
cal procedures were performed to obtain clinical changes
in peri-implant bone levels. Implant cover screws were
replaced by appropriate healing abutments, followed by
single interrupted sutures for re-adaptation of the flap.
Patients returned in 2 weeks for suture removal. During
this period, new crowns were designed, fabricated and
delivered to all patients and for all treated implants.
2.4.9 Final recall (time point 3)
Three months after installment of new implant crowns,
at the initial post-surgical maintenance recall, PD mea-
surements were obtained as performed at the pre-surgical
visit (time point 0). Figure 2 demonstrates the study pro-




The primary endpoint of this study was to assess the
amount of clinical linear bone gain after the surgical recon-
structive treatment (time point 1) until the 8-month re-
entry (time point 2), through direct measurements of the
peri-implant osseous defects at all implant sites. This was
termed the clinical vertical defect fill (DF), and assessed at
each implant site (buccal, lingual/palatal, mesial, distal) as
follows:
DF = (Measurement at the surgical treatment) - (Mea-
surement at re-entry procedure)
The average changes at the 4 implant sites were calcu-
lated to present the implant score reflecting the average
clinical bone gain per treated implant.
2.5.2 Secondary outcomes
5. 2. 1. Radiographic bone gain
Two identical cone-beam computed tomography (CBCT)
scans*** were obtained following manufacturer instruc-
tions (90 kv, 3.2 mA, 15 s, 685 mGy.cm2, Voxel size: 150 μm
× 150 μm × 150 μm) from all patients at time point 0 (after
removal of suprastructures), and at time point 2 (before the
surgical re-entry) to evaluate the changes in radiographic
bone levels at 4 implant sites. Similar to the direct clini-
cal measurements of the peri-implant defects, the highest
point of each implant platform served as the reference for
the measurements, until the first visible bone-to-implant
contact. All radiographic assessments were performed by a
calibrated radiologist (C-Y.W), after initial calibration ses-
sions, and an intra-examiner reproducibility rate of at least
85% on randomly selected scans. Extra attention was paid
during this process to ensure reproducible measurements
for each scan, by identification of at least three distinct
anatomical landmarks on each CBCT slice (sagittal/cross-
sectional) to serve as references between time points.
Measurements were performed identically at both time
points to assess the changes at each peri-implant site to
comprise the vertical radiographic defect fill (RDF) per
implant sits:
RDF = (Measurement at the per-surgical appointment)
- (Measurement at 8 months)
Similar to the DF, the changes for the four peri-implant
sites were averaged to present the implant score relative to
RDF.
*** Carestream Dental LLC, CS 8100 3D, Atlanta, USA
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F IGURE 2 An example of a treated peri-implantitis case in the current study from initiation up to completion of the study. (A and B)
radiographic and clinical representation of the infected implants before removal of the suprastructures. (C) immediately after removal of
suprastructures. (D and E) Occlusal and buccal view of the infected implants after flap elevation. (F) Implantoplasty procedure. (G) Use of an
air-abrasive device for debridement of peri-implant defects. (H and I) Augmentation procedure with the application of a composite bone graft
material and a perforated non-resorbable barrier membrane. (J) Fixation of the membrane using titanium screws on the buccal and lingual
aspect. (K) Immediately after flap closure and obtaining a primary wound coverage. (L) At the two-week post-op before suture removal.
(M) Cross-sectional slices of the cone-beam computed tomography scan at the three treated implants during the 8-month recall. (N) Surgical
re-entry procedure at 8 months for removing the non-resorbable membrane followed by obtaining defect measurements. (O and P) Buccal,
and occlusal views of the regenerated peri-implant bone. (Q) After re-fabrication and installment of new implant prostheses. (R) At the
3-month visit following installment of new prosthesis and obtaining final clinical measurements. (S) Two-dimensional radiographic
representation of the treated implants 3 months after placement of new prosthetic suprastructures. (T) Coronal/cross-sectional CBCT slice
before- (left, at time point 0), and after-regenerative therapy (right, at time point 2) of the most distal implant in the presented case
5. 2. 2. Peri-implant PD and BOP reduction
Changes in PD from time point 0 (before removal of
suprastructures) to time point 3 (final recall) were calcu-
lated to obtain the PD reduction at each of the sixmeasured
peri-implant sites as follows:
PD reduction = (Measurement at pre-surgical appoint-
ment) - (Measurements at the final recall)
The average changes of the six peri-implant sites were
also obtained for descriptive purposes.
BOP was assessed dichotomously (Yes/No) at both time
points, for any implant that presented with a positive BOP
at any of the six probable sites, and expressed as a percent-
age of the total treated implants at the specific time point.
2.6 Outcome assessment and statistical
analysis
Means and standard deviations (SD) were calculated
for continuous outcomes (DF, RDF, PD) to descriptively
present the gathered clinical data at each time point. BOP
was assessed dichotomously and expressed as a percentage
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of implantswith a site of bleeding at timepoint 0, and at the
final recall (time point 3). Linear mixed-regression models
were used for statistical assessment of changes in the pri-
mary outcome of DF, as well as the secondary outcomes of
RDF, and PDwith respect to time and treatment (8months
for DF and RDF, and 12 months for PD). Random effects
were included for patient, for implant within patients, and
for the implant site ofmeasurement per implant in patients
(three-way interaction) to account for repeated measures
(multiple implants in some patients, and multiple mea-
surement sites per each implant), along with a fixed effect
for time. Model assumptions were tested. The coefficients
that present the rate of change for each outcome with
respect to time were recorded. Confidence intervals (CIs)
were produced, and a P value of 0.05 was set for statisti-
cal significance. The average changes in DF, RDF, and PD
reduction (per implant) were also obtained for descriptive
purposes.
The data management and statistical analyses were per-
formed by a separate author with experience in statistical
methodology, who had not participated in any of the mea-
surements or collection of data (S.B), with a specified soft-
ware †††, and the statistical packages lme4 ,25 and dplyr.26
3 RESULTS
3.1 Population and implant
characteristics
Twenty-two patients with a total of 30 implant fixtures
were included and treated in this study. The population
sample included 12 males and 10 females with an average
age of 56 ± 13.14 years. All implants were bone level with
various implant systems, located in the posterior region (22
molar sites, and eight premolars), and had been in function
for at least 2 years before the diagnosis of peri-implantitis.
Twenty-two of the treated implants were located in the
mandibular region, and eight in the maxilla. Six patients
had more than one implant treated, whereas the rest all
had only a single implant that was treated. Seven patients
reported the use of tobacco, which was <5 cigarettes/day,
and 18 patients had had a history of periodontal disease
and/or treatment for a periodontal condition at some point
in the past. The characteristics of the treated sample are
presented in Table 1.
All participants completed the study without any
dropouts, or implant extractions. Patients were compli-
ant to the prescribed medications and the study follow-
up recalls, and aside from two cases of delayed (beyond
2 weeks) membrane exposure, no unexpected or major
†††Rstudio Version 1.1.383, Rstudio, Inc., MA, USA
TABLE 1 Characteristics of the treated sample at baseline
Category Characteristic Value
Patient Male (n, %) 12, 55%
Female (n, %) 10, 45%








Implant Maxillary arch (n, %) 8, 22%
Mandibular arch (n, %) 22, 73%
Premolar sites (n, %) 8, 22%







n corresponds to the number of patients/implants based on the category pre-
sented in the left column; SD, standard deviation.
complications had occurred. The two incidence of mem-
brane exposure were both small areas (less than about
5 mm2) that did not present with suppuration or dis-
charge and the patients that had noticed the exposurewere
instructed to rinse with a 0.2% chlorhexidine mouth rinse,
and apply a chlorhexidine-soaked cotton swab twice daily
onto the area, until they were removed at 6 weeks.
3.2 Primary outcome of direct
measurements of linear bone gain after 8
months of submerged healing
The change rates based on the mixed model for each clin-
ical measure between the two respective time points are
presented in Table 2, and the average gain/reduction of the
clinical parameters is shown in Table 3. Figure 3 presents
clinical and radiographic images from pre-treatment until
the follow-up time point of three cases that were treated as
part of this study.
At the time of the surgical treatment, the average clini-
calmeasurements of the peri-implant osseous defects were
3.37 mm ± 1.88, 2.95 ± 1.66, 3.48 ± 1.60 mm, and 3.63 ±
1.85 on the buccal, lingual/palatal, mesial, and distal sites,
respectively. During the surgical re-entry, the obtained
measurements for the same peri-implant sites were 0.16 ±
1.86, 0.15 ± 1.66, -0.17 ± 1.86, and 0.4 ± 1.36 mm, respec-
tively (negative sign indicates bone overgrowth relative to
the implant platform).
According to the mixed model (Table 2), all
changes were statistically significant and amounted to
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TABLE 2 Results of the mixed-effects regression analysis demonstrating the rates of change for the assessed clinical parameters between











Buccal -3.321 0.25 -3.82, -2.81 <0.001 Time points 1
and 2Lingual -2.803 0.25 -3.31, -2.28 <0.001
Mesial -3.656 0.27 -4.19, -3.11 <0.001
Distal -3.226 0.27 -3.77, -2.68 <0.001
Radiographic vertical
defect measurements
Buccal -3.483 0.27 -4.03, -2.93 <0.001 Time points 0
and 2Lingual -2.993 0.27 -3.53, -2.45 <0.001
Mesial -3.836 0.27 -4.38, -3.28 <0.001
Distal -3.603 0.27 -4.15, -3.04 <0.001
Peri-implant probing
depth measures
Mesio-buccal -2.966 0.29 -3.55, -2.37 <0.001 Time points 0
and 3Buccal -3.133 0.30 -3.74, -2.52 <0.001
Disto-buccal -3.033 0.25 -3.54, -2.52 <0.001
Disto-lingual -2.80 0.26 -3.32, -2.27 <0.001
Lingual -2.766 0.33 -3.43, -2.10 <0.001
Mesio-lingual -2.733 0.26 -3.25, -2.21 <0.001
Abbreviation: mm, millimeter; SE, standard error; CIs, Confidence intervals.
Note that changes for clinical and radiographic vertical defect measurements, negative coefficients represent gain in the observed outcomes, whereas for probing
depth measures negative scores represent reduction in scores. .
TABLE 3 Changes in the clinical outcomes per implant according to different time points
Study time point
Outcome Time point 0 Time point 1 Time point 2 Time point 3 Changes*
DF (mm ± SD) 3.36 ± 1.74 0.13 ± 1.69 3.22 ± 0.41
RDF (mm ± SD) 3.79 ± 1.66 0.31 ± 1.75 3.47 ± 0.41
PD (mm ± SD) 5.81 ± 1.48 2.91± 1.11 2.93 ± 0.25
BOP (%) 100% 36.6% 63.3%
Abbreviations: mm, millimeter; SD, standard deviation.
DF, clinical vertical defect fill reported as the average of the four peri-implant sites.
RDF, radiographic vertical defect fill reported as the average of the four peri-implant sites.
PD, peri-implant probing depth reported as the average of the six peri-implant sites.
BOP, bleeding on probing assessed dichotomously per implant for any of the six peri-implant site that presented with bleeding at the time of assessment. Changes
in BOP are represent percentage in reduction.
*Note that changes for DF, and RDF are calculated through subtraction of the initial time point from the secondary time point.
Changes in PD are calculated convey reduction scores as subtraction of the secondary time point from the initial time point.
3.21 ± 1.3 mm in clinical bone gain on the buccal, 2.8 ±
1.4mmon the lingual/palatal, 3.66± 1.4mmon themesial,
and 3.23 ± 1.4 mm on the distal aspects. The average gain
for all implant sites amounted to 3.22 ± 0.41 mm (Table 3).
3.3 Radiographic bone gain
The initial radiographic (CBCT) measurements of the
defects after crown removal showed 4.03 ± 1.58, 3.22 ± 1.8,
3.89 ± 1.56, and 4.01 ± 1.70 mm on average for the peri-
implant sites of buccal, lingual/palatal, mesial, and dis-
tal, respectively. The corresponding measurements of the
four implant sites at the 8-month re-entry demonstrated
measurements of 0.55 ± 1.64, 0.22 ± 1.86, 0.05 ± 1.89,
and 0.4 ± 1.62 mm, respectively. The resulting changes,
based on the mixed model amounted to RDF of 3.48 ±
1.5 mm on the implants’ buccal sides, 2.99 ± 1.48 mm on
the lingual/palatal aspects, followed by 3.84± 1.5 mm, and
3.6 ± 1.5 mm on the mesial and distal sites, respectively.
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F IGURE 3 Clinical and radiographic images from pre-treatment until the follow-up time point of three treated cases as part of this
study. Note that images with A markings display baseline (pre-treatment) representation of defects, whereas B illustrate the outcomes after 8
months of submerged regenerative healing
All changes presented with statistical significance (P val-
ues < 0.001, Table 2), and an overall implant score of 3.47
± 0.41 mm for RDF (Table 3).
3.4 Peri-implant PD reduction and
bleeding on probing
Initial PD measurements before the treatment averaged
to 5.83 ± 1.42, 6.10 ± 1.52, 6.07 ± 1.2, 5.83 ± 1.58 mm,
5.70 ± 1.6, and 5.33 ± 1.56 mm on the mesio-buccal,
buccal, disto-buccal, disto-lingual, lingual, and mesio-
lingual sides, respectively. At the final study recall, 3
months after installment of new crowns, the correspond-
ing values averaged to 2.87 ± 1.11, 2.97 ± 1.1, 3.03 ±
1.19, 3.03 ± 1.03, 2.93 ± 1.34, and 2.60 ± 0.89 mm,
respectively.
Overall, a significant PD reduction was observed at the
final recall for all treated sites as a result of the combined
surgical and prosthetic therapy, amounting 2.97 ± 1.6, 3.13
± 1.6, 3.03 ± 1.5, 2.81 ± 1.4, 2.76 ± 1.8, and 2.73 ± 1.4 mm
(P values < 0.001, Table 2), and an average implant PD
reduction score of 2.93 ± 0.25 mm (Table 3). In addition, a
significant reduction in BOP from 100% to 36.6% was also
observed from the pre-surgical visit (time point 0) until the
final recall (time point 3).
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The date pertaining to all investigated outcomes, at their
respective time points are also further presented in Table
S1.
4 DISCUSSION
In the present study, we observed a considerable improve-
ment in all clinical measurements, and a significant recon-
struction of infraosseous peri-implantitis defects with the
submerged healing approach.
Whendiscussing the treatment of peri-implantitis, a pre-
requisite for obtaining successful outcomes, is manage-
ment of its etiology. In part, this entails thorough debride-
ment of the peri-implant defect, proper decontamination
of the implant surface, and removal of potential con-
tributing factors to the peri-implant diseases. In addition,
removal of implant suprastructures before the surgical pro-
cedure, allowed for a greater access to the osseous defects,
and implant surfaces at the time of detoxification. Replace-
ment of cover screws at least 1 month before the regen-
erative therapy also led to the expansion of adjacent soft
tissues before the procedure, which is an advantage on its
own for such bone augmentation procedures .27 Last, in
the prospect of obtaining long-term success and avoiding
treatment relapse, carefully re-fabricated restorations were
provided to all patients as part of the study.
The choice for our selected biomaterials, relative to the
application of a non-resorbable membrane stemmed from
its wide and predictable use in regenerative procedures
.28–30 One of the corner stones of a successful bone regen-
erative therapy is the ability to maintain the augmented
space with a stable biomaterial ,31,32 in which blood clot
formation, angiogenesis, and eventual bone regeneration
can occur .31,33 This, along with other properties of dPTFE
membranes 34–37 fortified our decision towards selection of
this biomaterial for the regenerative protocol. In addition,
small perforations were also made on the membranes to
aid in blood supply and minimize the possibility of mem-
brane exposure. Indeed, only two incidences of a minor
membrane exposurewere observed,which presentedwith-
out purulence and the membranes were removed later on,
without an apparent compromise to the regenerative out-
comes.
Relative to our choice of bone grafting material, we
sought to obtain a cell-containing biomaterial filler capa-
ble of triggering osteoblastic migration and differentiation,
growth factor release, and formation of new mineralized
tissues, without the need for excessive autogenous harvest-
ing/scraping, as well as one that would exhibit a lower
biodegradability to serve as a longer lasting scaffold38–40
to maintain the augmented space over the intended 8-
month period. Although to the best of our knowledge no
other study on the treatment of peri-implantitis reports
the application of suchmixture, similar combinations, and
with varying ratios of autogenous and allogenic/xenogenic
bovine bone have been used for horizontal and vertical
ridge augmentation in the oral cavity.41–43
Thus far, most of the human research on the reconstruc-
tive treatment of peri-implantitis has involved the use of a
non-submerged approach,18–21,44 and the few studies that
have used a submerged approach, have assessed slightly
different outcomes or at alternative time points .14,45,46 At
this moment, no other human study has strictly assessed
the outcomes of a submerged healing for peri-implantitis
through direct clinical examinations of bone fill, a virtue of
the necessity to remove the non-resorbablemembrane and
fixation screws, that we defined as our primary outcome.
Therefore, a direct comparison of our results, in particular
our primary endpoint to the literature may not be feasible.
Schwarz et al. was the first to conduct a comparison
of the submerged and non-submerged approach in an
animal model47. The authors concluded that although
both groups obtained significant improvements in clinical
parameters, the implants in the submerged group achieved
better outcomes, and showed greater re-osseointegration
potential47. Roos-Jansåker et al. in 12 patients with peri-
implantitis-affected Brånemark implants, used a sub-
merged protocol,46 and radiographically assessed the
changes in bone levels, which averaged to 2.3 mm in
defect fill (ranging from 1 to 5.1 mm) at 6 months. Inter-
estingly the same group had also conducted a previous
study that included a non-submerged regenerative group
and had obtained less favorable results.48 The authors had
concluded that the undisturbed wound healing by a sub-
merged approach may have led to the differences in their
regenerative outcomes.
A recent randomized clinical trial comparing two bioab-
sorbable membranes (collagen, and concentrated growth
factor) with a bovine bone for a submerged protocol,
reported a mean RDF of 1.98 ± 0.7, and 1.63 ± 1 mm in
either groups 12 months after the reconstructive treatment
(obtained through averaging mesial and distal peri-apical
radiographic bone levels).14 The authors had also reported
a significant BOP reduction of 77 to 80% in both treatment
arms at 6 months,14 which is slightly higher than our find-
ings 3 months after installment of new implant crowns.
This difference may be attributable to a more stringent
BOP assessment that was applied in our study, as even a
single BOP-positive site per six, would render the implant
BOP-positive, contrary to the study by Isler et al.
In a more recent study, Monje et al. treated 27 implants
in 15 patients with peri-implantitis using a submerged
healing approach .45 Relative to the augmentation, the
authors used a mixture of an autogenous and xenogenic
bovine bone with the application of an absorbable
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collagen membrane, and assessed the outcomes with peri-
apical radiographs at 1 year, reporting a significant gain
of 2.2 mm (ranging 0 to 8.6 mm) in marginal bone lev-
els, and 3.7 mm reduction in PD (0.7 to 5.9).45 The many
design-driven differences, and baseline characteristics of
the referenced report relative to ours (the chosen biomate-
rials, outcome assessment, initial defect characteristics, re-
fabrication of all crowns, etc.) could have led to a greater
gain in the mean mesial/distal radiographic scores in our
study (3.72 ± 1.41 mm), and the lower PD reductions (2.93
± 0.25 mm).
Despite the advantage that can be obtained with a sub-
merged healing approach, readers should bear in mind
that removal of the implant suprastructure, especially
weeks before the regenerative procedure, can be challeng-
ing for many to accept, in particular when re-fabrication of
a crown may be indicated (such as cement retained pros-
thesis, or overly contoured restorations). This portion of
the treatment, although indeed beneficial, can also accom-
pany certain challenges. Aside from patients’ acceptance,
or the clinician’s own motivation towards this additional
step, it should also be considered that achieving a pri-
mary wound closure in such cases is technique sensi-
tive, and the required flap release is also likely to accom-
pany a greater post-operative patient morbidity. Therefore,
future randomized studies in the area of reconstructive
peri-implantitis therapy are needed to quantify the added
value of a submerged healing protocol with suprastruc-
ture removal, and its cost-effectiveness compared to a non-
submerged approach, or one wherein temporary removal
of suprastructures are done merely to facilitate decontam-
ination.
In the current study it was our aim to evaluate the
potential reconstructive capacity of confined infraosseous
peri-implantitis defects. Therefore, our results should
be interpreted with caution as not all peri-implantitis
defects may be favorable for regeneration. Although
confirmation of defect morphology and the degree of
bone loss was obtained after flap reflection and granula-
tion tissue removal, careful examination of pre-surgical
CBCT scans (at time point 0) allowed for this pre-
liminary assessment, especially as crown removal had
led to enhanced radiographic images and less scatter
radiation.
Indeed, the lack of a non-submerged treatment arm,
different types of bone level implants, or a control group
relative to the biomaterial selection (grafting materials,
barrier membranes) may limit the generalizability of our
results. Nonetheless, as data pertaining to the submerged
healing approach is scarce in the literature, and the treat-
ment of peri-implantitis is a challenging task to accom-
plish, we sought to use a gold standard protocol with
the most chance of success in our view. Furthermore, it
must be mentioned that true and definitive regeneration
can only be assessed through histological biopsies, which
was not performed in our study. Lastly, we deem neces-
sary future randomized studies to explore other facets rel-
ative to the reconstructive aspect, as well as long-term
follow-up investigations in the context of possible treat-
ment relapse, and the ability of the reconstructed bone
to stably support the treated implants under occlusal
forces.
5 CONCLUSION
Considering the limitations of this study, it can be con-
cluded that a submerged healing approach for the surgi-
cal reconstructive treatment of peri-implantitis can lead
to significant reconstruction of the lost peri-implant sup-
porting bone. This can be attributed to the merits pro-
vided by the removal of the implant suprastructures that
allow for enhanced peri-implant defect debridement and
implant surface detoxification, as well as the possibility to
obtain a primary coverage and undisturbedwound healing
throughout the regenerative process.
ACKNOWLEDGMENTS
The authors express their gratitude to Chung-YuWu (Med-
ical Radiologist, Shih-Hwa Dental Implant Center, Taipei
County, Taiwan) for performing the radiographicmeasure-
ments.
CONFL ICT OF INTEREST
The authors declare no potential conflict of interest with
respect to publication of this report or the enlisted and
materials within this manuscript.
FUNDING INFORMATION
The authors do not have any financial interests, either
directly nor indirectly, in the products or information listed
in the paper.
AUTHOR CONTRIBUTIONS
Shih-ChengWen: Conception and design of the study; per-
formed the surgical procedures, initial and final drafting
of the work; Final approval of the version to be published;
accountable for all aspects of the work.
Shayan Barootchi: Design of the study, acquisition, and
interpretation of data and analyses, manuscript prepa-
ration and the initial draft, final reviewal of the work;
accountable for all aspects of the work.
12 WEN et al.
Wen-Xia Huang: Conception and study design, contri-
bution to manuscript writing, critical review of the final
draft, accountable for all aspects of the work.
Hom-Lay Wang: Design of the study; critical review of
the draft and contribution to thewriting of themanuscript;
Final approval of the version to be published and account-
able to the accuracy or integrity of the work.
DATA AVAILAB IL ITY STATEMENT
The data that support the findings of this study are avail-






1. Berglundh T, Armitage G, MG, et al. Peri-implant diseases and
conditions: Consensus report of workgroup 4 of the 2017 World
Workshop on the Classification of Periodontal and Peri-Implant
Diseases and Conditions. J Periodontol 2018;89(suppl 1):S313-
S318.
2. Derks JC, Peri-implant health and disease. A systematic
review of current epidemiology. J Clin Periodontol 2015;42(suppl
16):S158-171.
3. Mombelli A, Muller N, N, The epidemiology of peri-implantitis.
Clin Oral Implants Res 2012;23(suppl 6):67-76.
4. Ramseier CA, Eick S, Bronnimann C, Buser D, Bragger U, GE,
Host-derived biomarkers at teeth and implants in partially eden-
tulous patients. A 10-year retrospective study.ClinOral Implants
Res 2016;27:211-217.
5. Zitzmann NU, T, Definition and prevalence of peri-implant dis-
eases. J Clin Periodontol 2008;35:286-291.
6. Suarez-Lopez Del Amo F, Yu SH, HL, Non-surgical therapy for
peri-implant diseases: a systematic review. J Oral Maxillofac Res
2016;7:e13.
7. Faggion CM, Jr, Chambrone L, Listl S, YK, Network meta-
analysis for evaluating interventions in implant dentistry: the
case of peri-implantitis treatment. Clin Implant Dent Relat Res
2013;15:576-588.
8. Lindhe J, Meyle J, Group DoEWoP. Peri-implant diseases: con-
sensus Report of the Sixth European Workshop on periodontol-
ogy. J Clin Periodontol 2008;35:282-285.
9. Barootchi S, Ravida A, Tavelli L, Wang HL. Nonsurgical treat-
ment for peri-implant mucositis: a systematic review and meta-
analysis. Int J Oral Implantol (Berl) 2020;13:123-139.
10. Carcuac O, Derks J, Abrahamsson I, Wennstrom JL, Petzold
M, Berglundh T. Surgical treatment of peri-implantitis: 3-year
results from a randomized controlled clinical trial. J Clin Peri-
odontol 2017;44:1294-1303.
11. Hallstrom H, Persson GR, Lindgren S, Renvert S. Open flap
debridement of peri-implantitis with or without adjunctive sys-
temic antibiotics: a randomized clinical trial. J Clin Periodontol
2017;44:1285-1293.
12. Schwarz F, John G, Schmucker A, Sahm N, Becker J. Com-
bined surgical therapy of advanced peri-implantitis evaluating
two methods of surface decontamination: a 7-year follow-up
observation. J Clin Periodontol 2017;44:337-342.
13. deWaal YC, Raghoebar GM,Meijer HJ,Winkel EG, vanWinkel-
hoff AJ. Prognostic indicators for surgical peri-implantitis treat-
ment. Clin Oral Implants Res2016;27:1485-1491.
14. Isler SC, Soysal F, Ceyhanli T, Bakirarar B, Unsal B. Regenera-
tive surgical treatment of peri-implantitis using either a collagen
membrane or concentrated growth factor: a 12-month random-
ized clinical trial. Clin Implant Dent Related Res 2018;20:703-712.
15. Larsson L, Decker AM, Nibali L, Pilipchuk SP, Berglundh T,
Giannobile WV. Regenerative medicine for periodontal and
peri-implant diseases. J Dental Res 2016;95:255-266.
16. Aghazadeh A, Rutger Persson G, Renvert S. A single-centre ran-
domized controlled clinical trial on the adjunct treatment of
intra-bony defects with autogenous bone or a xenograft: results
after 12 months. J Clin Periodontol 2012;39:666-673.
17. Renvert S, Roos-Jansaker AM, Persson GR. Surgical treat-
ment of peri-implantitis lesions with or without the use of a
bone substitute-a randomized clinical trial. J Clin Periodontol
2018;45:1266-1274.
18. Galarraga-Vinueza ME, Obreja K, Magini R, Sculean A, Sader
R, Schwarz F. Volumetric assessment of tissue changes follow-
ing combined surgical therapy of peri-implantitis: a pilot study.
J Clin Periodontol 2020.
19. Daugela P, Cicciu M, Saulacic N. Surgical regenerative treat-
ments for peri-implantitis: meta-analysis of recent findings in
a systematic literature review. J Oral Maxillofac Res 2016;7:e15.
20. de Tapia B, Valles C, Ribeiro-Amaral T, et al. The adjunctive
effect of a titanium brush in implant surface decontamination at
peri-implantitis surgical regenerative interventions: a random-
ized controlled clinical trial. J Clin Periodontol 2019;46:586-596.
21. Jepsen K, Jepsen S, Laine ML, et al. Reconstruction of peri-
implant osseous defects: a multicenter randomized trial. J Den-
tal Res 2016;95:58-66.
22. Katafuchi M, Weinstein BF, Leroux BG, Chen YW, Daubert
DM. Restoration contour is a risk indicator for peri-implantitis:
a cross-sectional radiographic analysis. J Clin Periodontol
2018;45:225-232.
23. O’Leary TJ, Drake RB, Naylor JE. The plaque control record. J
Periodontol 1972;43:38.
24. Wen S-CH, W-X; Wang, H-L. Regeneration of peri-implantitis
infrabony defects: report on three cases. Int J Periodontics
Restorat Dent 2019;39.
25. Bates DM, M; Bolker, B; Walker, S. Fitting linear mixed-effects
models using lme4. J Statis Software 2015;67:1–48.
26. WickhamHF, R; Henry, L,Müller K., dplyr: AGrammar of Data
Manipulation. 2019.
27. Byun SH, Kim SY, LeeH, et al. Soft tissue expander for vertically
atrophied alveolar ridges: prospective, multicenter, randomized
controlled trial. Clin Oral Implants Res 2020;31:585-594.
28. BarberHD, Lignelli J, SmithBM,BarteeBK.Using a dense PTFE
membrane without primary closure to achieve bone and tissue
regeneration. J Oral Maxillofacial Surge 2007;65:748-752.
29. Wen SC, Barootchi S, Huang WX, Wang HL. Time analysis of
alveolar ridge preservation using a combination of mineralized
bone-plug and dense-polytetrafluoroethylene membrane: a his-
tomorphometric study. J Periodontol 2020;91:215-222.
30. Urban IA, Monje A, Lozada JL, Wang HL. Long-term evalua-
tion of peri-implant bone level after reconstruction of severely
WEN et al. 13
atrophic edentulous maxilla via vertical and horizontal guided
bone regeneration in combination with sinus augmentation: a
case serieswith 1 to 15 years of loading.Clin ImplantDentRelated
Res 2017;19:46-55.
31. Wang HL, Boyapati L. “PASS” principles for predictable bone
regeneration. Implant Dent 2006;15:8-17.
32. Simion M, Jovanovic SA, Trisi P, Scarano A, Piattelli A. Vertical
ridge augmentation around dental implants using a membrane
technique and autogenous bone or allografts in humans. Int J
Periodontics Restorative Dent 1998;18:8-23.
33. Sigurdsson TJ, Hardwick R, Bogle GC,Wikesjo UM. Periodontal
repair in dogs: space provision by reinforced ePTFEmembranes
enhances bone and cementum regeneration in large supraalve-
olar defects. J Periodontol 1994;65:350-356.
34. Carbonell JM, Martin IS, Santos A, Pujol A, Sanz-Moliner
JD, Nart J. High-density polytetrafluoroethylene membranes in
guided bone and tissue regeneration procedures: a literature
review. Int J Oral Maxillofacial Surge 2014;43:75-84.
35. Walters SP, Greenwell H, Hill M, Drisko C, Pickman K, Scheetz
JP. Comparison of porous and non-porous teflon membranes
plus a xenograft in the treatment of vertical osseous defects: a
clinical reentry study. J Periodontol 2003;74:1161-1168.
36. Laurito D, Cugnetto R, LollobrigidaM, et al. Socket Preservation
with d-PTFEmembrane: histologic analysis of the newly formed
matrix at membrane removal. Int J Periodontics Restorative Dent
2016;36:877-883.
37. Urban IA, Lozada JL, Jovanovic SA, Nagursky H, Nagy K.
Vertical ridge augmentation with titanium-reinforced, dense-
PTFE membranes and a combination of particulated auto-
genous bone and anorganic bovine bone-derived mineral: a
prospective case series in 19 patients. Int J Oral Maxillofacial
Implants 2014;29:185-193.
38. Galindo-Moreno P, Hernandez-Cortes P, Aneiros-Fernandez J,
et al. Morphological evidences of Bio-Oss(R) colonization by
CD44-positive cells. Clin Oral Implants Res 2014;25:366-371.
39. SanzM, Dahlin C, Apatzidou D, et al. Biomaterials and regener-
ative technologies used in bone regeneration in the craniomax-
illofacial region: consensus report of group 2 of the 15th Euro-
peanWorkshop on Periodontology on Bone Regeneration. J Clin
Periodontol 2019;46(Suppl 21):82-91.
40. Zhang X, Tiainen H, Haugen HJ. Comparison of titanium
dioxide scaffold with commercial bone graft materials through
micro-finite element modelling in flow perfusion. Med Biologi-
cal Eng Computing 2019;57:311-324.
41. Ronda M, Rebaudi A, Torelli L, Stacchi C. Expanded vs. dense
polytetrafluoroethylene membranes in vertical ridge augmen-
tation around dental implants: a prospective randomized con-
trolled clinical trial. Clin Oral Implants Res 2014;25:859-866.
42. Urban IA,MonjeA,NevinsM,NevinsML, Lozada JL,WangHL.
Surgical management of significant maxillary anterior vertical
ridge defects. Int J Periodont Restorat Dent 2016;36:329-337.
43. Simion M, Fontana F, Rasperini G, Maiorana C. Vertical ridge
augmentation by expanded-polytetrafluoroethylene membrane
and a combination of intraoral autogenous bone graft and depro-
teinized anorganic bovine bone (BioOss).ClinOral Implants Res
2007;18:620-629.
44. Schwarz F, Sahm N, Iglhaut G, Becker J. Impact of the
method of surface debridement and decontamination on the
clinical outcome following combined surgical therapy of peri-
implantitis: a randomized controlled clinical study. J Clin Peri-
odontol 2011;38:276-284.
45. Monje A, Pons R, Roccuzzo A, Salvi GE, Nart J. Reconstructive
therapy for the management of peri-implantitis via submerged
guided bone regeneration: a prospective case series. Clinical
Implant Dentistry and Related Research 2020;22:342-350.
46. Roos-JansakerAM,RenvertH, LindahlC, Renvert S. Submerged
healing following surgical treatment of peri-implantitis: a case
series. J Clin Periodontol 2007;34:723-727.
47. Schwarz F, Jepsen S, Herten M, Sager M, Rothamel D, Becker J.
Influence of different treatment approaches on non-submerged
and submerged healing of ligature induced peri-implantitis
lesions: an experimental study in dogs. J Clin Periodontol
2006;33:584-595.
48. Roos-Jansaker AM, Renvert H, Lindahl C, Renvert S. Surgical
treatment of peri-implantitis using a bone substitute with or
without a resorbable membrane: a prospective cohort study. J
Clin Periodontol 2007;34:625-632
SUPPORT ING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
How to cite this article: Wen S-C, Barootchi S,
Huang W-X, Wang H-L Surgical reconstructive
treatment for infraosseous peri-implantitis defects
with a submerged healing approach: A prospective
controlled study. J Periodontol. 2021;1-13.
https://doi.org/10.1002/JPER.21-0161
